Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population

Asian Journal of Andrology

Volumn 17, Issue 1, 2015, Pages 98-105

  Megas, Georgios ^a   Chrisofos, Michael ^b   Anastasiou, Ioannis ^c   Tsitlidou, Aida ^a   Choreftaki, Theodosia ^a   Deliveliotis, Charalampos ^d  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d SISMANOGLIO HOSPITAL   (Greece)

Author keywords

androgen receptor; estrogen receptor ( ); estrogen receptor ( ); locally advanced prostate cancer; radical prostatectomy

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; GLEASON SCORE; GREEK (PEOPLE); HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; URBAN AREA; AGED; DISEASE COURSE; EPIDEMIOLOGY; FOLLOW UP; GREECE; INCIDENCE; METABOLISM; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; BIOMARKERS, TUMOR; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOLLOW-UP STUDIES; GREECE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REGRESSION ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84920366309     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.136445     Document Type: Article

References (57)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49: 1374-403.
2. Itsiopoulos C, Hodge A, Kaimakamis M. Can the Mediterranean diet prevent prostate cancer? Mol Nutr Food Res 2009; 53: 227-39.
3. Tzonou A, Signorello LB, Lagiou P, Wuu J, Trichopoulos D, et al. Diet and cancer of the prostate: a case-control study in Greece. Int J Cancer 1999; 80: 704-8.
4. Stamatiou K, Lardas M, Kostakos E, Koutsonasios V, Lepidas D. Prostate cancer screening in Greece: current facts. Urol J 2009; 6: 157-61.
5. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-52.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
7. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90: 162-73.
8. Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, et al. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. Eur Urol 2011; 60: 554-63.
9. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54.
10. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-71.
11. Hodgson D, Warde P, Gospodarowicz M. The management of locally advanced prostate cancer. Urol Oncol 1998; 4: 3-12.
12. Fallon B, Williams RD. Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 1990; 17: 853-66.
13. Boccon-Gibod L, Bertaccini A, Bono AV, Dev Sarmah B, Höltl W, et al. Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 2003; 57: 187-94.
14. Bolla M, Collette L, Blank L, Warde P, Dubois JB, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6.
15. Yamada AH, Lieskovsky G, Petrovich Z, Chen SC, Groshen S, et al. Results of radical prostatectomy and adjuvant therapy in the management of locally advanced, clinical stage TC, prostate cancer. Am J Clin Oncol 1994; 17: 277-85.
16. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 1997; 32: 385-90.
17. van den Ouden D, Hop WC, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998; 160: 1392-7.
18. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6.
19. Hsu CY, Joniau S, Oyen R, Roskams T, Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007; 51: 121-8.
20. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-8.
21. Ding Y, Yuan HQ, Kong F, Hu XY, Ren K, et al. Ectopic expression of neurotrophic peptide derived from saposin C increases proliferation and upregulates androgen receptor expression and transcriptional activity in human prostate cancer cells. Asian J Androl 2007; 9: 601-9.
22. Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, et al. Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 2007; 9: 181-8.
23. Qiu YQ, Leuschner I, Braun PM. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review. Asian J Androl 2008; 10: 855-63.
24. Chang WY, Prins GS. Estrogen receptor-beta: implications for the prostate gland. Prostate 1999; 40: 115-24.
25. Ho SM. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004; 91: 491-503.
26. Risbridger GP, Ellem SJ, McPherson SJ. Estrogen action on the prostate gland: a critical mix of endocrine and paracrine signaling. J Mol Endocrinol 2007; 39: 183-8.
27. Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer 2008; 44: 928-36.
28. Carruba G. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 2007; 102: 899-911.
29. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996; 28: 98-106.
30. Bosland MC. The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention. Rev Urol 2005; 7 Suppl 3: S4-10.
31. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 2008; 22: 1512-20.
32. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-69.
33. Goulding H, Pinder S, Cannon P, Pearson D, Nicholson R, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 1995; 26: 291-4.
34. Thike AA, Chng MJ, Fook-Chong S, Tan PH. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology 2001; 33: 21-5.
35. Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol 1972; 34: 187-202.
36. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006; 58: 773-81.
37. Yang GS, Wang Y, Wang P, Chen ZD. Expression of oestrogen receptor-alpha and oestrogen receptor-beta in prostate cancer. Chin Med J (Engl) 2007; 120: 1611-5.
38. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 2001; 159: 79-92.
39. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, et al. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res 2001; 61: 5331-5.
40. Latil A, Bièche I, Vidaud D, Lidereau R, Berthon P, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 2001; 61: 1919-26.
41. Fixemer T, Remberger K, Bonkhoff H. Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate 2003; 54: 79-87.
42. Emtage LA, Dunn PJ, Rowse AD. Androgen and oestrogen receptor status in benign and neoplastic prostate disease. Study of prevalence and influence on time to progression and survival in prostate cancer treated by hormone manipulation. Br J Urol 1989; 63: 627-33.
43. Klein EA. Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention. Rev Urol 2002; 4 Suppl 5: S18-28.
44. Hempstock J, Kavanagh JP, George NJ. Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. Br J Urol 1998; 82: 560-3.
45. Cohen DA, Dabbs DJ, Cooper KL, Amin M, Jones TE, et al. Interobserver agreement among pathologists for semiquantitative hormone receptor scoring in breast carcinoma. Am J Clin Pathol 2012; 138: 796-802.
46. Gnanapragasam VJ, Robson CN, Leung HY, Neal DE. Androgen receptor signalling in the prostate. BJU Int 2000; 86: 1001-13.
47. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991; 67: 3057-64.
48. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, et al. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 1992; 147: 798-803.
49. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735-46.
50. Lee DK, Chang C. Endocrine mechanisms of disease: expression and degradation of androgen receptor: mechanism and clinical implication. J Clin Endocrinol Metab 2003; 88: 4043-54.
51. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, et al. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996; 77: 934-40.
52. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, et al. Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996; 28: 129-35.
53. Li R, Wheeler T, Dai H, Frolov A, Thompson T, et al. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004; 28: 928-34.
54. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-9.
55. Dunsmuir WD, Gillett CE, Meyer LC, Young MP, Corbishley C, et al. Molecular markers for predicting prostate cancer stage and survival. BJU Int 2000; 86: 869-78.
56. Crowe FL, Key TJ, Appleby PN, Travis RC, Overvad K, et al. Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2008; 87: 1405-13.
57. Hsieh CC, Thanos A, Mitropoulos D, Deliveliotis C, Mantzoros CS, et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999; 80: 699-703.